Inactive Instrument

News Galapagos NV Euronext Bruxelles

Stocks

GLPG

BE0003818359

Biotechnology & Medical Research

End-of-day quote Euronext Bruxelles
-	-

09-23	Lakefront Biotherapeutics' Gamgertamig Has Meaningful Opportunity in Rare Autoimmune Diseases, RBC Says	MT
09-23	RBC Upgrades Lakefront Biotherapeutics to Outperform From Sector Perform, Adds Speculative Risk, Raises Price Target to $45 From $26	MT

All News

Mentions Relevance

09-29	Acquisition of Own Shares	GL
09-23	Lakefront Biotherapeutics' Gamgertamig Has Meaningful Opportunity in Rare Autoimmune Diseases, RBC Says	MT
09-23	RBC Upgrades Lakefront Biotherapeutics to Outperform From Sector Perform, Adds Speculative Risk, Raises Price Target to $45 From $26	MT
09-22	Acquisition of Own Shares	GL
09-16	Lakefront Biotherapeutics NV Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 05:35 PM
09-15	Acquisition of Own Shares	GL
09-08	Acquisition of Own Shares	GL
09-08	Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference	GL
09-01	Acquisition of Own Shares	GL
08-25	Acquisition of Own Shares	GL
08-24	U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus	GL
08-24	Lakefront Receives Transparency Notification from Bank of America	GL
08-18	Acquisition of Own Shares	GL
08-12	Acquisition of Own Shares	GL
08-12	Tranche Update on Lakefront Biotherapeutics NV's Equity Buyback Plan announced on June 9, 2026.	CI
08-11	RBC Adjusts PT on Lakefront Biotherapeutics to $26 From $28, Keeps Sector Perform Rating	MT
08-11	Morgan Stanley Adjusts PT on Lakefront Biotherapeutics to $26 From $30, Maintains Equalweight Rating	MT
08-11	Lakefront Biotherapeutics H1 Net Profit From Continuing Operations EUR15.8 Mln	RE
08-10	Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update	GL
08-10	Lakefront Biotherapeutics NV Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-04	Acquisition of Own Shares	GL
07-28	Acquisition of Own Shares	GL
07-21	Acquisition of Own Shares	GL
07-14	Acquisition of Own Shares	GL
07-13	Lakefront Biotherapeutics NV Announces Resignation of Paulo Fontoura as Director	CI